The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 13
Abstract
Background: Anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are key factors in the American College of Rheumatology/European League Against Rheumatism rheumatoid arthritis (RA) classification criteria markers. However, about 30% of patients diagnosed with RA are seronegative, rationalizing the need for new serologic markers for RA. Antibodies against carbamylated proteins (anti-CarP) and against peptidyl-arginine deiminase type 4 (anti-PAD4) have been postulated to be useful RA markers. The purpose of this study is to evaluate the value of anti-CarP and anti-PAD4 in a well-characterized population of RA patients and healthy controls (HCs). Methods: A total of 122 RA patients and 30 HCs were enrolled in the study. Serum levels of ACPA, anti-PAD4, anti-CarP and RF were determined by enzyme-linked immunosorbent immunoassays (ELISAs). Synthetic carbamylated peptides were used in the ELISA assay to determine the protein targets of the anti-CarP antibodies. Results: Rates of ACPA, RF, anti-PAD4 and anti-CarP positivity were 85.2%, 67.2%, 55.7% and 46.7% in RA, and 0%, 0%, 6.7% and 6.7% in HC respectively. In the RA population, 25.4% of patients had all four types of antibodies positive, while 6.6% had no antibodies. There was a significant correlation between anti-PAD4 and ACPAs ( rs = 0.39), RF and ACPAs, ( rs = 0.3) and RF and anti-CarP, ( rs = 0.3). There was no correlation between ACPAs and anti-CarP. Anti-CarP positivity was noted in 49 (47.1%) and 45 (54.9%) of ACPAs and RF positive patients respectively. In addition, five anti-CarP+ patients did not have ACPA nor RF. Conclusion: Anti-CarP but not anti-PAD4 may be a useful biomarker in identifying ACPA/RF negative RA patients. This antibody may identify an additional RA population who may benefit from early implementation of aggressive therapy.Keywords
This publication has 49 references indexed in Scilit:
- Erosive Rheumatoid Arthritis Is Associated with Antibodies That Activate PAD4 by Increasing Calcium SensitivityScience Translational Medicine, 2013
- Performance of Anti–Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established DiseaseArthritis & Rheumatism, 2013
- Autoimmunity in rheumatoid arthritis: different antigens—common principlesAnnals of the Rheumatic Diseases, 2013
- NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid ArthritisScience Translational Medicine, 2013
- Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritisAutoimmunity Reviews, 2012
- Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damageProceedings of the National Academy of Sciences, 2011
- The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgiaAnnals of the Rheumatic Diseases, 2011
- Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritisArthritis & Rheumatism, 2010
- Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activationArthritis & Rheumatism, 2010
- Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-α blocking agentsAnnals of the Rheumatic Diseases, 2009